newsfilter
← Latest News
GlobeNewswire·

HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer

  • HCW Biologics Inc. (NASDAQ: HCWB) announced its data update for HCW11-040 was selected as one of the Top 150 abstracts out of 1,200 submissions for the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
  • HCW11-040 is a first-in-class, second-generation, tetravalent pembrolizumab-based immune checkpoint inhibitor developed using the company's proprietary non-Fc TRBC platform.
  • The molecule is constructed with interleukin domains (IL-15 & IL-7) paired with a TGF-β trap to potentially rejuvenate exhausted T cells for enhanced cancer cell killing.
  • Preclinical studies show HCW11-040 outperformed standard immune checkpoint inhibitors in converting immunological cold tumors to hot tumors for solid tumor immunotherapy.
  • The company will present Abstract #394 titled "A tetravalent, pembrolizumab-based fusion immunotherapeutic protein targeting exhausted T cells for expansion and activation" during the Poster Session on Saturday, November 7, 2026.
  • HCW11-040 combines immune checkpoint blockade with cytokine-mediated immune activation to enhance CD8+ T-cell migration to tumors & reduce immunosuppression in the tumor microenvironment.
  • The mouse homologue HCW11-050 demonstrated superior anti-solid-tumor activities against cold tumors compared to immune checkpoint inhibitors in various preclinical models.
  • HCW Biologics is a clinical-stage biopharmaceutical company focused on multi-valent immunotherapeutics without the antibody Fc domain to treat autoimmune diseases, cancer, & senescence-associated dysplasia.
Company
HCW Biologics, Inc
Keywords
Nasdaq:HCWB, HCW Biologics, Inc, #hcwbSITC, #HCWBICI, #SITCtop150